logo-loader

THC Global has full suite of cannabis licences to advance farm-to-pharma model

Published: 14:46 26 Jun 2019 AEST

Ken Charteris
Group CEO Ken Charteris at the company's cannabis cultivation site at Bundaberg, Queensland. Photo credit: ABC Wide Bay, Kallee Buchanan

THC Global Group Ltd (ASX:THC) operates under a farm-to-pharma pharmaceutical model, now holding all three key cannabis licences being a Cannabis Research Licence, a Medicinal Cannabis Licence (Cultivation), and a Manufacture Licence.

The company has secured a significant cannabis growing capacity over multiple cultivation projects and owns a pharmaceuticals bio-manufacturing facility with attached testing and product development laboratory.

Bundaberg cannabis cultivation site manager John Hall. Photo credit: ABC Wide Bay, Kallee Buchanan

THC is in a prime position to commence medicinal cannabis production to service both domestic patients and the global export market.

The company is active globally with operations in Australia, New Zealand, and Canada and partnerships across Europe, Asia, and the Middle East.

In addition to its core Australian medicinal cannabis assets, THC has a significant Canadian presence – both in cannabis and in hydroponics equipment.

 

THC’s Canadian cannabis operation, Vertical Canna, holds property in Nova Scotia, Canada being developed into a large-scale cannabis production site.

The company’s hydroponics equipment division, Crystal Mountain, is a revenue generating manufacturer, wholesaler, and retailer of hydroponics equipment and supplies.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

7 hours, 55 minutes ago